![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
X
20
Phalanx Labs Private Limited Hyderabad In, based in India, is a pharmaceutical company.
One of their significant offerings is Levetiracetam, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R0-CEP 2015-319 - Rev 00
This Chemical Type CEP, issued on December 16, 2016, remains in force until March 17, 2021, ensuring its reliability within the pharmaceutical industry.
Substance Number 2535 associated with this CEP further emphasizes